Intracranial Efficacy of Selpercatinib in Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial
Author
Subbiah, VivekGainor, Justin F
Oxnard, Geoffrey R
Tan, Daniel S W
Owen, Dwight H
Cho, Byoung Chul
Loong, Herbert H
McCoach, Caroline E
Weiss, Jared
Kim, Yu Jung
Bazhenova, Lyudmila
Park, Keunchil
Daga, Haruko
Besse, Benjamin
Gautschi, Oliver
Rolfo, Christian
Zhu, Edward Y
Kherani, Jennifer F
Huang, Xin
Kang, Suhyun
Drilon, Alexander
Date
2021-06-18Journal
Clinical Cancer ResearchPublisher
American Association for Cancer ResearchType
Article
Metadata
Show full item recordAbstract
We report the intracranial efficacy of selpercatinib, a highly potent and selective RET inhibitor, approved in the United States for RET fusion-positive non-small cell lung cancers (NSCLC).Rights/Terms
©2021 American Association for Cancer Research.Keyword
LIBRETTO-001 TrialRET fusion-positive NSCLC
selpercatinib
Carcinoma, Non-Small-Cell Lung--drug therapy
Identifier to cite or link to this item
http://hdl.handle.net/10713/16059ae974a485f413a2113503eed53cd6c53
10.1158/1078-0432.CCR-21-0800
Scopus Count
Collections
Related articles
- Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer.
- Authors: Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V
- Issue date: 2020 Aug 27
- Efficacy and safety of selpercatinib in Chinese patients with advanced <i>RET</i> fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321).
- Authors: Lu S, Cheng Y, Huang D, Sun Y, Wu L, Zhou C, Guo Y, Shao J, Zhang W, Zhou J
- Issue date: 2022
- Selpercatinib in Patients With <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial.
- Authors: Drilon A, Subbiah V, Gautschi O, Tomasini P, de Braud F, Solomon BJ, Shao-Weng Tan D, Alonso G, Wolf J, Park K, Goto K, Soldatenkova V, Szymczak S, Barker SS, Puri T, Bence Lin A, Loong H, Besse B
- Issue date: 2022 Sep 19
- [Efficacy and Safety Analysis of Selpercatinib in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer-Results from the Japanese Subset of a Global Phase 1/2 Study].
- Authors: Nishio M, Ohe Y, Ohashi K, Toyozawa R, Satouchi M, Sekine N, Mori J, Enatsu S, Goto K
- Issue date: 2022 Jun
- Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
- Authors: Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, Takeda M, Ohe Y, Khan S, Ohashi K, Soldatenkova V, Szymczak S, Sullivan L, Wright J, Drilon A
- Issue date: 2022 Oct